Genetically engineered virulent phages to detect and control emergent pathogenic bacteria
Pherecydes Pharma is proud to announce the publication of it first scientifique paper in: Bioscurity and Bioterrorism: Biodefense Strategy, Practice and Science.
Launching of our Phage Industry Newsletter !
We are pleased to introduce our quarterly bulletin entitled The Phage Industry Newsletter.
Participation at the French Biotech Tour
French and American biotech companies met on March 15 and 17 2010 to see how they can collaborate to develop effective therapeutics and diagnostics to combat infectious diseases. MRSA and other bacterial threats have been a few of the hot topics.
8th ASM Biodefense & Emerging Diseases Conference
For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.
Phage Industry News Letter
 |
Phages are about to become essential for biotechnology developments in industrialized countries. Used mainly in the former soviet block from the early 30’s to nowadays, bacteriophages are now gaining interest into western countries. Antibiotic and antiseptic failures against a wide range of bacterial strains certainly opens the door to such products.
As a new actor in this world, we were puzzled by the lack of information related to our nascent industry and decided to create The Phage Industry News Letter, dedicated to bacteriophages and their practical use.
|
Each quarterly edition will deal with a domain using full or parts of living or dead phages. Topics will address diagnostic, therapy, disinfection, animal care, nanowires… Voluntarily focused on industrial applications, the minute will enable companies to have their say about technological data, markets to be conquered or strategic events.
Création & hébergement : Infini'click